Core Viewpoint - The company,透景生命, announced a plan to acquire 82% of 康录生物 for a total of 3.28 billion yuan, aiming to revitalize its growth after three consecutive years of poor performance [1][6][10]. Group 1: Acquisition Details - The acquisition will occur in three phases, starting with the purchase of 72.8630% of 康录生物, followed by additional purchases in 2026 and 2027 if certain conditions are met [6][20]. - 康录生物 specializes in the FISH technology field and has developed rapid FISH reagents and automated detection equipment, positioning itself as a leader in molecular diagnostics [7][8]. Group 2: Financial Performance - 透景生命 has experienced a decline in profits for three consecutive years, with revenue dropping from 7.16 billion yuan in 2022 to 5.43 billion yuan in 2023 [11][12]. - The company’s net profit for 2023 was reported at 89.4 million yuan, down from 124.76 million yuan in 2022 [12]. Group 3: Strategic Rationale - The acquisition is expected to create synergies in development strategy, market channels, and product technology, potentially leading to new revenue and profit growth [3][9]. - The FISH products from 康录生物 are anticipated to enhance 透景生命's product matrix and provide comprehensive solutions in tumor diagnostics [8][10]. Group 4: Risks and Commitments - The acquisition includes a performance guarantee of over 90 million yuan over three years, with specific annual profit targets set for 康录生物 [20][21]. - 康录生物's recent financial performance indicates challenges in meeting these targets, having reported revenues of 97.3 million yuan and a net profit of 16.96 million yuan in 2024 [22].
“昂贵”并购引发股价“两连跌” 透景生命扩张得与失